Ofloxacin 200 mg + Ornidazole 500 mg

OFLARGE-OZ Suspension
Ofloxacin 50 mg + Ornidazole 125 mg

Oflarge-OZ has in vitro activity against a broad spectrum of gram-positive and gram-negative aerobic and
anaerobic bacteria.


Ofloxacin is thought to exert a bactericidal effect on susceptible microorganisms by inhibiting DNA gyrase, an
essential enzyme that is a critical catalyst in the duplication, transcription, and repair of bacterial DNA.
Ofloxacin has been shown to be active against most strains of the following microorganisms both in vitro and
in specific clinical infections.

Gram-positive Aerobes: Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus pyogenes.
Gram-negative Aerobes: Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Haemophilus
influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Proteus mirabilis, Pseudomonas aertiginosa
Other: Chlamydia trachomatis.


Ornidazole is a 5-nitroimidazole derivative with actions similar to Metronidazole and Tinidazole and is used
in the treatment of susceptible Protozoal Infections and also in Anaerobic Bacterial Infections.
It is effective against Protozoa including Entamoeba histolytica, Giardia lambia and Trichomonas spp and
Bacteria such as Bacteriodes spp., Anaerobic cocci, Fusobacterium spp., Clostridum spp., and Gardenerlla
vaginas. It acts by damage of DNA strands or inhibition of their synthesis.

Both Ofloxacin and Ornidazole are almost completely absorbed from the small intestine when administered
orally both having almost 100% bioavailability. Subsequent plasma concentrations of Ofloxacin are obtained
in 1-2 hours after oral administration. Peak plasma concentrations of Ornidazole are obtained within 2 hours
of administration.

The plasma elimination of Ornidazole is 12 to 15 hours and less than 15% is bound to plasma proteins. It is
widely distributed in body tissues and fluids. Ornidazole is metabolised in the liver and is excreted in the urine
mainly as metabolites and conjugates and to a lesser extent in the faces.


Oflarge-OZ is indicated for the treatment of a wide variety of infections caused by susceptible gram-positive
and gram-negative organisms along with anaerobes and protozoa.

-> Gynaecological infections including prophylaxis in gynaecological surgeries.
-> Surgical prophylaxis and surgical wound infections.
-> Respiratory tract infections like lung abscess, aspiration pneumonia, empyema and bronchiectasis ENT
infections like chronic sinusitis, chronic suppurative otitis media, cholesteatoma and mastoiditis.
-> Orofacial and dental infections.
-> Dermatological infections like cellulitis, breast and other cutaneous abscesses, angrene, diabetic and
decubitus ulcers.
-> Intra-abdominal infections and diarrhoeas of mixed bacterial and protozoal origin


The usual adult dose is one tablet of Olsa-OZ twice a day. The doses may be increased in severe infections. The
duration of treatment depends upon the type and severity of infection.


The overall benefits of the combination of ofloxacin and ornidazole include:
1. Broad spectrum coverage of both bacteria and protozoa in a variety of infections.
2. A possible synergistic effect against some species of anaerobic bacteria such as B. fragilis.
3. Empiric therapy for polymicrobial infection in patients in whom it is difficult to identify the organism.
4. Combination of one of the most potent fluoroquinolones against gram-negative enteric organisms
and gram-positive aerobic organisms and a highly potent agent against protozoa.
5. Since the combination is in a fixed dose, it ensures that the patient gets both the drugs against
bacteria and protozoa.
6. Significant improvement in compliance since the number of pills to be taken by the patient is reduced
by half.
7. There are no interactions between the two drugs.
8. Both the drugs are well tolerated and have been used for several years

  • SCF 377, Sector 13 Chandigarh - 160047
Enquire Us
close slider

    Inquire Us